Literature DB >> 2049230

A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction.

J D Gemmill1, K J Hogg, J M Burns, A P Rae, F G Dunn, R Fears, H Ferres, R Standring, H Greenwood, D Pierce.   

Abstract

1. The pharmacokinetics of streptokinase (SK) and anistreplase in conventional dosage regimens of 1.5 x 10(6) i.u. of SK infused over 60 min and 30 units of anistreplase over 5 min were studied in 24 consecutive patients presenting with acute myocardial infarction, using a functional bioassay to assess concentrations. 2. The two agents were found to have similar volumes of distribution (5.68 and 5.90 l), but SK was cleared significantly more rapidly than anistreplase, resulting in a shorter terminal phase half-life (0.61 vs 1.16 h) and a shorter mean residence time (0.76 vs 1.55 h).

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2049230      PMCID： PMC1368380          DOI： 10.1111/j.1365-2125.1991.tb05502.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  20 in total

1.  The clearance of heterologous protein from the circulation of normal and immunized man.

Authors:  A P FLETCHER; N ALKJAERSIG; S SHERRY
Journal:  J Clin Invest       Date:  1958-09       Impact factor: 14.808

2.  Improved survival after early thrombolysis in acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute in The Netherlands.

Authors:  M L Simoons; P W Serruys; M vd Brand; F Bär; C de Zwaan; J Res; F W Verheugt; X H Krauss; W J Remme; F Vermeer
Journal:  Lancet       Date:  1985-09-14       Impact factor: 79.321

3.  Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921.

Authors:  M Been; D P de Bono; A L Muir; F E Boulton; W S Hillis; R Hornung
Journal:  Br Heart J       Date:  1985-03

4.  A randomized trial of IV streptokinase in evolving acute myocardial infarction: an assessment by selective coronary angiography.

Authors:  M Khalilullah; D Natarajan; V K Bahl; M R Babu; S Tyagi; U A Kaul
Journal:  Indian Heart J       Date:  1984 Nov-Dec

5.  The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

Authors:  S Riegelman; P Collier
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

6.  A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction.

Authors:  J L Anderson; H W Marshall; J C Askins; J R Lutz; S G Sorensen; R L Menlove; F G Yanowitz; A D Hagan
Journal:  Circulation       Date:  1984-10       Impact factor: 29.690

7.  The effects of the rate of intravenous infusion of streptokinase and the duration of symptoms on the time interval to reperfusion in patients with acute myocardial infarction.

Authors:  A S Lew; P Laramee; B Cercek; L Rodriguez; P K Shah; W Ganz
Journal:  Circulation       Date:  1985-11       Impact factor: 29.690

8.  Clinical effects and kinetic properties of intravenous APSAC--anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction.

Authors:  M Been; D P de Bono; A L Muir; F E Boulton; R Fears; R Standring; H Ferres
Journal:  Int J Cardiol       Date:  1986-04       Impact factor: 4.164

9.  Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.

Authors:  M Verstraete; R Bernard; M Bory; R W Brower; D Collen; D P de Bono; R Erbel; W Huhmann; R J Lennane; J Lubsen
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

10.  Acute myocardial infarction treated with intracoronary streptokinase: a report of the Society for Cardiac Angiography.

Authors:  J W Kennedy; G G Gensini; G C Timmis; C Maynard
Journal:  Am J Cardiol       Date:  1985-04-01       Impact factor: 2.778
View more
  6 in total

1.  A rapid agglutination assay to detect anti-streptokinase antibodies.

Authors:  J P McRedmond; N T Mulvihill; M Kane; B Burke; B Aloul; T Forde; M Walsh; D J Fitzgerald
Journal:  Ir J Med Sci       Date:  2004 Oct-Dec       Impact factor: 1.568

2.  Circulatory concentrations of fibrinolytic species during thrombolytic therapy estimated by stirred-tank reactor analysis.

Authors:  V V Tuliani; E A O'Rear
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 3.  Drug interactions with thrombolytic agents. Current perspectives.

Authors:  A de Boer; J M van Griensven
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 4.  Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.

Authors:  P E Battershill; P Benfield; K L Goa
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923

5.  Effect of streptokinase on reperfusion after acute myocardial infarction and its complications: an ex-post facto study.

Authors:  Leila Taheri; Ali Zargham Boroujeni; Marzieh Kargar Jahromi; Maryam Charkhandaz; Mohsen Hojat
Journal:  Glob J Health Sci       Date:  2015-01-01

6.  Co-ordinated spatial propagation of blood plasma clotting and fibrinolytic fronts.

Authors:  Ansar S Zhalyalov; Mikhail A Panteleev; Marina A Gracheva; Fazoil I Ataullakhanov; Alexey M Shibeko
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.